PDB Entry - 6DCG
(Status - Released)Summary information:
Title: Discovery of MK-8353: An Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology
PDB DOI: https://doi.org/10.2210/pdb6dcg/pdb
Primary publication DOI: https://doi.org/10.1021/acsmedchemlett.8b00220
Entry authors: Boga, S.B., Deng, Y., Zhu, L., Nan, Y., Cooper, A., Shipps Jr., G.W., Doll, R., Shih, N., Zhu, H., Sun, R., Wang, T., Paliwal, S., Tsui, H., Gao, X., Yao, X., Desai, J., Wang, J., Alhassan, A.B., Kelly, J., Patel, M., Muppalla, K., Gudipati, S., Zhang, L., Buevich, A., Hesk, D., Carr, D., Dayananth, P., Mei, H., Cox, K., Sherborne, B., Hruza, A.W., Xiao, L., Jin, W., Long, B., Liu, G., Taylor, S.A., Kirschmeier, P., Windsor, W.T., Bishop, R., Samatar, A.A.
Initial deposition on: 6 May 2018
Initial release on: 8 August 2018
Latest revision on: 11 October 2023
Downloads:
Structure coordinates (PDBx/mmCIF)
Structure coordinates (PDBML)
Structure coordinates (PDB)
X-ray diffraction data (PDBx/mmCIF)
Validation report (XML)
Validation report (mmCIF)
Validation report (PDF)
Links to more resources for 6DCG at: